Related Experiment Video
Updated: May 29, 2026

Operational and Intervention Effects of Targeted Tuina in Lumbar Intervertebral Disc Degeneration Model Rabbits
Published on: July 21, 2023
Emerging technologies for molecular therapy for intervertebral disk degeneration
1Department of Radiology, University of California San Diego, San Diego, CA 92103-8226, USA.
Abstract:
Intervertebral disks are biologically regulated by the maintenance of a balance between the anabolic and catabolic activities of disk cells. Therapeutic agents, initially evaluated using in vitro studies on disk cells and explants, have been used as intradiscal injections in preclinical settings to test in vivo efficacy. These include anabolic growth factors, other biostimulatory agents, and antagonistic agents against matrix-degrading enzymes and cytokines. Additional work is needed to identify patient populations, using methods such as MRI, and to better understand the mechanism of healing. Clinical trials are underway for a few of these agents and other promising candidates are on the horizon.
Insights
Researchers are exploring new therapies for intervertebral disc degeneration by balancing anabolic and catabolic cell activities. Promising agents are advancing to clinical trials for disc healing.
Area of Science:
- Biomedical Engineering
- Regenerative Medicine
- Orthopedics
Background:
- Intervertebral disc (IVD) degeneration is driven by an imbalance in cellular anabolic and catabolic activities.
- Maintaining this biological balance is crucial for disc health and function.
Purpose of the Study:
- To review therapeutic strategies targeting intervertebral disc degeneration.
- To assess the efficacy of agents evaluated in preclinical and in vitro settings.
Main Methods:
- In vitro studies on disc cells and explants.
- Preclinical in vivo efficacy testing of therapeutic agents via intradiscal injections.
- Review of agents including growth factors, biostimulatory compounds, and matrix-degrading enzyme inhibitors.
Main Results:
- Various therapeutic agents show potential in preclinical models.
- Anabolic growth factors and matrix-degrading enzyme inhibitors are among promising candidates.
- Intradiscal injections are a key delivery method for in vivo testing.
Conclusions:
- Further research is needed to identify optimal patient populations using imaging like MRI.
- Understanding the mechanisms of disc healing is essential for therapeutic development.
- Several promising agents are progressing towards or are in clinical trials for disc regeneration.
Related Concept Videos
Degenerative Disc Disease I: Introduction
Degenerative Disc Disease ll: Pathophysiology
Herniated Intervertebral Disc l: Introduction

